* CorMedix Inc is expected to show a rise in quarterly revenue when it reports results on October 30 for the period ending September 30 2024
* The Berkeley Heights New Jersey-based company is expected to report revenue of $10.839 million, according to the mean estimate from 4 analysts, based on LSEG data.
* LSEG's mean analyst estimate for CorMedix Inc is for a loss of 10 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for CorMedix Inc is 13.50, above its last closing price of $13.04.
This summary was machine generated October 28 at 13:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments